Humalog Articles
US FDA warns Lilly on insulin API manufacturing violations and Roche and Abbott over HIV combo drug concerns
24 February 2010
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
Lilly swings to loss on ImClone acquisition
9 February 2009
Lilly swings into loss in 3rd qtr on legal costs
3 November 2008
FDA clears Sanofi's Apidra for children
3 November 2008
Lilly's 4th qtr recovers from Zyprexa settlement
4 February 2008
Eli lilly sees 3rd qtr net income climb 6% as sales jump 19% to $4.6B, raises full-year guidance
29 October 2007
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Lilly halts Va insulin plant construction
22 January 2007
Lilly's 3rd-qtr 2006 profit rises 10% on Zyprexa
30 October 2006
Lilly launches Humalog rapid insulin in USA
13 February 2006
Strong 2003 sales for Lilly but profits flat
9 February 2004
Underlying growth beats forecasts at Lilly
28 April 2003
2003 will fall below forecast, says Eli Lilly
10 February 2003
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
Eli Lilly adding 5,000 more sales reps
26 October 2001
Novo insulin analog launched in USA
19 September 2001
New drugs lift Lilly's 2nd qtr sales 16%
23 July 2001
New drugs lift Lilly's 2nd qtr sales 16%
20 July 2001
Zyprexa takes over as Eli Lilly's top seller
26 January 2001
New products boost growth at Eli Lilly
20 October 2000
Eli Lilly's 2nd-qtr EPS increases 17%
25 July 2000
Lilly granted new indications for Humalog
4 May 2000
Eli Lilly Ranbaxy launches HumaPen
27 April 2000
Earnings rise 18% at Eli Lilly
17 April 2000
Eli Lilly suffers from poor Prozac sales
22 October 1999
Novo Nordisk's Prandin plus Rezulin, insulin
24 June 1999
Beyond Prozac : Lilly outlines future
14 June 1999
HMR files long-acting insulin glargine
28 April 1999
Lilly's Humalog Mix25 reaches the market
14 January 1999
Lilly's Humalog Mix25 Cleared In EU
24 December 1998
Novo Files For Insulin Analog In Europe
13 August 1998
Zyprexa: Lilly Files For Bipolar Disorder
18 December 1997
Pharma Strategies: M&A Or Technical Excellence?
3 March 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
Eli Lilly's Humalog Approved In Canada
28 October 1996
Lilly Signs $100 Million Antibiotic Deal With Dura
2 September 1996
Lilly Cuts Costs As It Launches New Products
15 July 1996
Humalog Cleared In UK, Approved In USA
24 June 1996
EMEA Approves Three More Products
3 June 1996
Lilly's Humalog Backed By FDA Committee
11 March 1996
Humalog Implications
11 March 1996
First Humalog Launch
26 February 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Eli Lilly's Humalog Gets Second Approval
9 October 1995
NEW YORK STOCK COMMENT
2 October 1995
Showing 1-71 of 71 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
